The Hodgkin lymphoma space found itself in the spotlight late last year when Affimed NV rolled out updated data with lead innate cell engager acimtamig when combined with allogeneic natural killer cells. Findings from the investigator-initiated trial became the topic of talk at the American Society of Hematology meeting, when Yago Nieto, professor at the University of Texas MD Anderson Cancer Center – and principal investigator of the study – spoke.
After raising HKD$320 million (US$40.8 million) in its IPO on the Hong Kong Stock Exchange last week, Immuneonco Biopharmaceuticals Co. Ltd.’s stock has continued to rise, and analysts are expecting the Hong Kong market to pick up after a slack start to the year.
Affimed NV said the latest data with its lead innate cell engager (ICE) known as AFM-13, disclosed at the American Society of Hematology (ASH) meeting, have caused the focus to shift from monotherapy to combination regimens.
Affimed NV and Artiva Biotherapeutics Inc. have entered into a new strategic partnership to jointly develop, manufacture and commercialize a combination therapy comprised of Affimed's Innate Cell Engager (ICE) AFM-13 and Artiva's cord blood-derived, cryopreserved off-the-shelf allogeneic natural killer (NK) cell product candidate, AB-101.
Akeso Inc. became the fifth company to score an approval for a homegrown PD-1 antibody in China, with penpulimab cleared for relapsed or refractory (r/r) classic Hodgkin’s lymphoma (cHL).
HONG KONG – Shanghai, China-based Immuneonco Biopharmaceuticals Co. Ltd. bagged $25 million in series B financing in October. The funding will mainly support the companies’ immunotherapies, which include IMM-01 and IMM-0306, both of which target CD47.
HONG KONG – Shanghai, China-based Immuneonco Biopharmaceuticals Co. Ltd. bagged $25 million in series B financing in October. The funding will mainly support the companies’ immunotherapies, which include IMM-01 and IMM-0306, both of which target CD47.
HONG KONG – Singapore-based Tessa Therapeutics Pte. Ltd. released the results of two investigator-initiated phase I/II trials that found its autologous CD30 CAR T-cell therapy TT-11 showed a high rate of durable complete responses and a favorable safety profile in patients with relapsed/refractory Hodgkin lymphoma.
HONG KONG – Singapore-based Tessa Therapeutics Pte. Ltd. released the results of two investigator-initiated phase I/II trials that found its autologous CD30 CAR T-cell therapy TT-11 showed a high rate of durable complete responses and a favorable safety profile in patients with relapsed/refractory Hodgkin lymphoma.
BEIJING – CAR T specialist Wuhan Bio-Raid Biotechnology Co. Ltd. said its BRD-01, an anti-CD30 CAR T therapy candidate, has been granted IND approval by China’s NMPA. It is the first CD30 candidate to enter the clinic stage amid an increasingly heated CAR T race dominated by candidates targeting CD19 and BMCA.